paclitaxel has been researched along with Hormone-Dependent Neoplasms in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (31.82) | 18.2507 |
| 2000's | 37 (56.06) | 29.6817 |
| 2010's | 8 (12.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, RH; Andreopoulou, E; Cristofanilli, M; Fehn, K; Fineberg, S; Han, HS; Hershman, DL; Pellegrino, CM; Raptis, G; Sparano, JA; Vahdat, LT; Valero, V; Vigoda, IS; Wright, JJ | 1 |
| Arbini, AA; Greco, M; Marra, E; Moro, L | 1 |
| Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF | 1 |
| Ettinger, S; Fazli, L; Gleave, ME; Hayashi, N; Kim, Y; Muramaki, M; Narita, S; So, A | 1 |
| Bachelot, T; Blay, JY; Favier, B; Fayette, J; Galy, G; Guastalla, JP; Labidi, SI; Mosbah, K; Ray-Coquard, I; Treilleux, I | 1 |
| Kiniwa, M; Kurebayashi, J; Nukatsuka, M; Sonoo, H; Uchida, J | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Bahri, S; Butler, JA; Carpenter, PM; Chen, JH; Feig, SA; Hsiang, DJ; Kuzucan, A; Lane, KT; Lin, M; Mehta, RS; Nalcioglu, O; Su, MY; Yu, HJ | 1 |
| Berretta, M; Cappellani, A; Cavallaro, A; Di Vita, M; Grosso, G; Lanzafame, S; Piccolo, G; Zanghì, A | 1 |
| Agus, DB; Cordon-Cardo, C; Drobnjak, M; Fox, WD; Higgins, B; Maiese, KM; Scher, HI | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Abdel-Mageed, AB; Agrawal, KC; Davis, R; Flynn, V; Moparty, K; Ramanitharan, A; Sikka, S | 1 |
| Davis, TL; Hauke, R; Kakitelashvilli, V; Kellerman, M; Lee, MS; Lin, MF; Lugo, E; Spellman, M; Taylor, R; Zelivianski, S; Zhou, XW | 1 |
| Curran, EM; Dougherty, MK; El-Ashry, D; Ellis, MJ; Jordan, VC; Schumaker, LM; Welshons, WV | 1 |
| Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP | 1 |
| Davidson, NE; Park, BH | 1 |
| Beraldi, E; Fazli, L; Gleave, M; Hurtado-Coll, A; Kojima, S; Rocchi, P; Signaevsky, M; So, A; Yamanaka, K | 1 |
| Barthomeuf, C; Bay, JO; Cabrespine, A; Chollet, P; Curé, H; Debiton, E | 1 |
| Chueh, SC; Guh, JH; Huang, DM; Huang, YT; Teng, CM | 1 |
| Asmar, L; Berry, W; Boehm, KA; Fleagle, J; Friedland, D; Ilegbodu, D; Jackson, D | 1 |
| Bekele, BN; Chen, I; Daliani, DD; Dieringer, PY; Logothetis, CJ; Mathew, P; Pagliaro, LC; Zhou, X | 1 |
| Mancuso, A; Oudard, S; Sternberg, CN | 1 |
| Anderson, K; Andre, F; Buchholz, TA; Buzdar, AU; Frye, D; Gonzalez-Angulo, AM; Hess, KR; Hortobagyi, GN; Kau, SW; Kuerer, HM; Mazouni, C; Pusztai, L; Symmans, WF | 1 |
| Aydiner, A; Karagol, H; Kucucuk, S; Saip, P; Topuz, E; Uygun, K | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Daskivich, TJ; Oh, WK; Regan, MM | 1 |
| Downing, KH; Killilea, AN; Killilea, DW | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| McBride, D | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Ling, MT; Wang, XH; Wong, YC; Zhang, XM | 1 |
| Chapman, A; Gallo, J; Greenberg, R; Hudes, GR; McAleer, C; Obasaju, C | 1 |
| Burkley, M; Kodali, S; Moudgil, VK; Nag, K; Taylor, RC | 1 |
| Roth, BJ | 1 |
| Christensen, C; Deppe, G; Lawrence, WD; Ruan, H; Saunders, DE; Wappler, NL | 1 |
| Alken, P; Köhrmann, KU; Kreukler, C; Nebe, T; Siegsmund, MJ; Steidler, A | 1 |
| Au, JL; Chen, CT; Gan, Y; Wientjes, MG | 1 |
| Pienta, KJ; Smith, DC | 1 |
| Baly, D; Beryt, M; Coombs, D; Hsu, S; Kabbinavar, F; Lewis, G; Pegram, M; Pietras, R; Slamon, D; Sliwkowski, M | 1 |
| Vogelzang, NJ | 1 |
| Stein, CA | 1 |
| Earhart, RH | 1 |
| Picus, J; Schultz, M | 1 |
| Cohen, J; Dimitt, B; Friedland, D; Gluckman, R; Keating, M; Lembersky, B; Miller, R; Reilly, N; Voloshin, M; Zidar, B | 1 |
| Bagiella, E; Benson, M; England-Owen, C; Hetjan, D; Judge, T; Macarthur, R; Newhouse, J; O'Connor, J; Olsson, C; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, A; Zuech, N | 1 |
| Budman, D; Kreis, W | 1 |
| Halabi, S; Hars, V; Kreis, W; Savarese, D; Taplin, ME; Vogelzang, N | 1 |
| Carducci, M; Eisenberger, M; Laufer, M; Sinibaldi, VJ | 1 |
| Kantoff, PW; Oh, WK | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Reese, DM; Small, EJ; Vogelzang, NJ | 1 |
| Gleave, ME; Miayake, H; Tolcher, A | 1 |
| Balczon, R; Chakrabarti, A; Hueser, CN; Ripple, M; Schatten, H; Taylor, M; Weindruch, R | 1 |
| Du, W; Flaherty, LE; Heilbrun, LK; Hussain, M; Kucuk, O; Redman, B; Trivedi, C | 1 |
| Kamradt, JM; Korenchuk, S; Muenchen, HJ; Pienta, KJ; Williams, JF | 1 |
| Bajorin, D; Ciolino, A; Curley, T; George, D; Heller, G; Kantoff, P; Kaufman, D; Kelly, WK; Larson, S; McCaffrey, J; Oh, W; Regan, K; Scher, H; Schwartz, L; Schwartz, M; Slovin, S; Small, EJ; Smith, M; Tong, W | 1 |
| Bova, GS; Isaacs, JT; Parikh, A; Pinski, J | 1 |
| Beckman, BS; Burow, ME; McLachlan, JA; Tang, Y; Weldon, CB | 1 |
| Heicappell, R | 1 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; McCauley, M; Reich, E; Richardson, P; Wheeler, C | 1 |
12 review(s) available for paclitaxel and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogens; Fatal Outcome; Female; Gallbladder Neoplasms; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Postmenopause; Progesterone; Radiotherapy, Adjuvant | 2011 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Epothilones; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 2007 |
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Receptors, Estrogen; Survival Analysis; Taxoids; Tumor Burden | 2007 |
New therapeutic agents for hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Estramustine; Humans; Male; Metalloendopeptidases; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine | 1996 |
Paclitaxel in the treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1999 |
Mechanisms of action of taxanes in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubules; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53 | 1999 |
Docetaxel (Taxotere): preclinical and general clinical information.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Hormone-refractory prostate cancer: an evolving standard of care.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
17 trial(s) available for paclitaxel and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Farnesyl-Diphosphate Farnesyltransferase; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2013 |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2 | 2011 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2006 |
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Disease Progression; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Thalidomide; Time Factors; Treatment Outcome | 2006 |
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Receptors, Estrogen; Survival Analysis; Taxoids; Tumor Burden | 2007 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Female; Humans; Male; Neoplasms; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1995 |
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 1999 |
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 1999 |
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Topics: Aged; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis | 2000 |
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2001 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Life Tables; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Progesterone; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Thiotepa; Time Factors; Treatment Outcome | 2002 |
38 other study(ies) available for paclitaxel and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma.
Topics: Androgens; Apoptosis; Carcinogens; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Cell Transformation, Neoplastic; DNA, Mitochondrial; Drug Resistance, Neoplasm; Ethidium; Humans; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms | 2008 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2008 |
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Humans; Kruppel-Like Transcription Factors; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Saccharomyces cerevisiae Proteins; Zinc Finger Protein Gli2 | 2008 |
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2009 |
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Estradiol; Estrogen Antagonists; Estrogens; Female; Fluorouracil; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, EphA2; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Thymidylate Synthase | 2010 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Receptors, Estrogen; Toremifene | 2010 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Contrast Media; Cyclophosphamide; Doxorubicin; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Trastuzumab; Treatment Outcome | 2011 |
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Topics: Androgens; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Disease Models, Animal; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; I-kappa B Proteins; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
Topics: Apoptosis; bcl-X Protein; Butadienes; Docetaxel; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Culture Media, Serum-Free; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptors, Steroid; Tumor Cells, Cultured | 2004 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Immunomagnetic Separation; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Neoplastic Cells, Circulating; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured | 2004 |
Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Estrogen Receptor alpha; Female; Humans; Neoplasms, Hormone-Dependent; Paclitaxel | 2004 |
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Disease Progression; Dose-Response Relationship, Drug; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering | 2004 |
In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzophenanthridines; Carboplatin; Drug Antagonism; Drug Synergism; Humans; In Vitro Techniques; Isotretinoin; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Phenanthridines; Prostatic Neoplasms; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Alisol B acetate, a triterpene from Alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells.
Topics: Alismataceae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspases; Cell Nucleus; Cholestenones; Curcumin; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Membrane Potentials; Mitochondria; Neoplasms, Hormone-Dependent; Nitric Oxide Synthase; Paclitaxel; Prostatic Neoplasms; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Cells, Cultured | 2006 |
Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Time Factors | 2007 |
Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Humans; Immunoenzyme Techniques; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Zinc | 2007 |
Study finds that hormone status may predict chemotherapy's effectiveness on breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Inactivation of ID-1 gene induces sensitivity of prostate cancer cells to chemotherapeutic drugs.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Inhibitor of Differentiation Protein 1; JNK Mitogen-Activated Protein Kinases; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cisplatin; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Tumor Cells, Cultured | 1994 |
Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caffeine; Cell Cycle; Cisplatin; Cytarabine; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Doxorubicin; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Tumor Cells, Cultured | 1997 |
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorescent Dyes; Genes, MDR; Male; Methotrexate; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine | 1997 |
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Cycle; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Receptor, ErbB-2; Recombinant Proteins; Thiotepa; Topoisomerase II Inhibitors; Transplantation, Heterologous; Trastuzumab; Treatment Outcome; Vinblastine | 1999 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2000 |
Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Cell Division; Centrosome; Dihydrotestosterone; DNA, Neoplasm; Humans; Male; Metribolone; Microscopy, Electron; Microscopy, Fluorescence; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Testosterone Congeners | 2000 |
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Humans; Inhibitory Concentration 50; Male; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Taxoids; Tumor Cells, Cultured | 2000 |
Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts.
Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Cycle; Cell Division; Coculture Techniques; Culture Media, Conditioned; Doxorubicin; G1 Phase; Humans; Male; Neoplasms, Hormone-Dependent; Osteoblasts; Paclitaxel; Prostatic Neoplasms; Resting Phase, Cell Cycle; Thapsigargin; Tumor Cells, Cultured | 2001 |
Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, bcl-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Paclitaxel; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |